e-Drug3D

2051

BELZUTIFAN

INN
BELZUTIFAN

cas 1672668-24-4

CLASS

ANTINEOPLASTIC
TREATMENT OF HIPPEL-LINDAU (VHL) DISEASE
INHIBITOR OF HYPOXIA-INDUCIBLE FACTOR-2 ALPHA (HIF-2A) TRANSCRIPTION FACTOR

ROUTE (list)

ORAL

ATC code

L01XX74

PK parameters

Tmax 1.5 HOUR
VD 130 LITER
Cl 7.3 LITER / HOUR
PPB 45 PERCENT
t1/2 14 HOUR

Solubility

INSOLUBLE IN WATER

Target

TARGET HYPOXIA-INDUCIBLE FACTOR-2 ALPHA

PDB
5T0T (CRYSTAL STRUCTURE OF PT2399 BOUND TO HIF2A-B, ARNT-B COMPLEX)

Download experimental 3D coordinates of 72Q with added hydrogens

Endothelial PAS domain-containing protein 1 UNIPROT Q99814

Download SDF file

Benzonitrile, 3-[[(1S,2S,3R)-2,3-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl]oxy]-5-fluoro

Formula:
C17H12F3NO4S

Calculated chemical properties:

MW 383.35
NB_atoms 26
XLogP 3.29
PSA 77.127
NB_HD 1
NB_HA 5
fsp3 0.24
Lipinski(0=no;1=yes) 1

FDA
NDA 215383 (label) INN (BELZUTIFAN) WELIREG (MERCK SHARP DOHME) APPROVAL= AP YEAR= 2021